| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmacology, University of Alberta, Edmonton, Alberta, T6G 2H7 Canada [D. E. L. d. M., T. M. A.], and Department of Oncology, Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2 Canada [L. M. P.]
The ability to selectively target liposomal anticancer drugs via specific ligands against antigens expressed on malignant cells could improve the therapeutic effectiveness of the liposomal preparations as well as reduce adverse side effects associated with chemotherapy. Long-circulating formulations of liposomes containing lipid derivatives of poly(ethyleneglycol) [sterically stabilized liposomes (SLs)] have been described previously, and new techniques have recently been developed for coupling monoclonal antibodies (Abs) at the poly(ethyleneglycol) terminus of these liposomes. Ab-targeted SLs [immunoliposomes (SILs)] containing entrapped anticancer drugs are predicted to be useful in the treatment of hematological malignancies such as B-cell lymphomas or multiple myeloma, in which the target cells are present in the vasculature.
The specific binding, in vitro cytotoxicity, and in vivo antineoplastic activity of doxorubicin (DXR) encapsulated in SILs coupled to monoclonal Ab anti-CD19 (SIL[anti-CD19]) were investigated against malignant B cells expressing CD19 surface antigens. Binding experiments with SI-L[anti-CD19] resulted in a 3-fold higher association of the SILs with a human CD19+ B lymphoma cell line (Namalwa) in comparison with nontargeted SLs. Using flow cytometry, fluorescently labeled SIL[anti-CD19] bound to B cells with no recognition of T cells in a mixture of B cells and T cells in culture. Nontargeted SLs demonstrated significantly lower recognition of either B cells or T cells. Targeted DXR-SIL[anti-CD19] displayed a higher cytotoxicity to B cells relative to DXR entrapped in nontargeted SLs.
Therapeutic experiments in severe combined immunodeficient mice implanted with Namalwa cells by the i.v. or i.p. routes resulted in significantly increased effectiveness of DXR-SIL[anti-CD19] compared to similar amounts of free DXR, DXR-SL (no Ab), or isotype-matched nonspecific Abs attached to DXR-SL. Single doses (3 mg/kg) of DXR-SIL[anti-CD19] administered i.v. resulted in a significantly improved therapeutic benefit, including some long-term survivors. From our results, we infer that targeted anti-CD19 liposomes containing the anticancer drug DXR may be selectively cytotoxic for B cells and may be useful in the selective elimination of circulating malignant B cells in vivo.
1 Supported by The Medical Research Council of Canada, Canada (UI-12411), SEQUUS Pharmaceuticals, Inc. (T. M. A.), and the National Cancer Institute of Canada with funds from the Canadian Cancer Society (L. M. P.).
2 To whom requests for reprints should be addressed, at Department of Pharmacology, University of Alberta, Edmonton, Alberta, T6G 2H7 Canada. Phone: (403) 492-5710; Fax: (403) 492-8078; E-mail: terry.allen@ualberta.ca.
Received 9/16/97. Accepted 6/ 2/98.
This article has been cited by other articles:
|
|
 |
|
  S. Song, D. Liu, J. Peng, H. Deng, Y. Guo, L. X. Xu, A. D. Miller, and Y. Xu Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo FASEB J, May 1, 2009; 23(5): 1396 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hussain, A. Pluckthun, T. M. Allen, and U. Zangemeister-Wittke Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system Mol. Cancer Ther., November 1, 2007; 6(11): 3019 - 3027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hussain, A. Pluckthun, T. M. Allen, and U. Zangemeister-Wittke Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL Mol. Cancer Ther., December 1, 2006; 5(12): 3170 - 3180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Allen, D. R. Mumbengegwi, and G. J.R. Charrois Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates Clin. Cancer Res., May 1, 2005; 11(9): 3567 - 3573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. van Broekhoven, C. R. Parish, C. Demangel, W. J. Britton, and J. G. Altin Targeting Dendritic Cells with Antigen-Containing Liposomes: A Highly Effective Procedure for Induction of Antitumor Immunity and for Tumor Immunotherapy Cancer Res., June 15, 2004; 64(12): 4357 - 4365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sapra and T. M. Allen Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes Clin. Cancer Res., April 1, 2004; 10(7): 2530 - 2537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sapra, E. H. Moase, J. Ma, and T. M. Allen Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab' Fragments Clin. Cancer Res., February 1, 2004; 10(3): 1100 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Eliaz, S. Nir, C. Marty, and F. C. Szoka Jr. Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes Cancer Res., January 15, 2004; 64(2): 711 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pastorino, C. Brignole, D. Marimpietri, G. Pagnan, A. Morando, D. Ribatti, S. C. Semple, C. Gambini, T. M. Allen, and M. Ponzoni Targeted Liposomal c-myc Antisense Oligodeoxynucleotides Induce Apoptosis and Inhibit Tumor Growth and Metastases in Human Melanoma Models Clin. Cancer Res., October 1, 2003; 9(12): 4595 - 4605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pastorino, C. Brignole, D. Marimpietri, P. Sapra, E. H. Moase, T. M. Allen, and M. Ponzoni Doxorubicin-loaded Fab' Fragments of Anti-disialoganglioside Immunoliposomes Selectively Inhibit the Growth and Dissemination of Human Neuroblastoma in Nude Mice Cancer Res., January 1, 2003; 63(1): 86 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sapra and T. M. Allen Internalizing Antibodies Are Necessary for Improved Therapeutic Efficacy of Antibody-targeted Liposomal Drugs Cancer Res., December 15, 2002; 62(24): 7190 - 7194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Lee, T. Tanaka, T. Murai, M. Kondo, J. Kimura, W. Su, T. Kitagawa, T. Ito, H. Matsuda, and M. Miyasaka Novel Chondroitin Sulfate-binding Cationic Liposomes Loaded with Cisplatin Efficiently Suppress the Local Growth and Liver Metastasis of Tumor Cells in Vivo Cancer Res., August 1, 2002; 62(15): 4282 - 4288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Waelti, N. Wegmann, R. Schwaninger, A. Wetterwald, C. Wingenfeld, B. Rothen-Rutishauser, and C. D. Gimmi Targeting HER-2/neu with Antirat Neu Virosomes for Cancer Therapy Cancer Res., January 1, 2002; 62(2): 437 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Eliaz and F. C. Szoka Jr. Liposome-encapsulated Doxorubicin Targeted to CD44: A Strategy to Kill CD44-overexpressing Tumor Cells Cancer Res., March 1, 2001; 61(6): 2592 - 2601. [Abstract] [Full Text]
|
|
|
|
|
|
M. Sugano, N. K. Egilmez, S. J. Yokota, F.-A. Chen, J. Harding, S. K. Huang, and R. B. Bankert Antibody Targeting of Doxorubicin-loaded Liposomes Suppresses the Growth and Metastatic Spread of Established Human Lung Tumor Xenografts in Severe Combined Immunodeficient Mice Cancer Res., December 1, 2000; 60(24): 6942 - 6949. [Abstract] [Full Text]
|
|
|
|
|
|
H. J. Lim, M. J. Parr, D. Masin, N. L. McIntosh, T. D. Madden, G. Zhang, S. Johnstone, and M. B. Bally Kupffer Cells Do Not Play a Role in Governing the Efficacy of Liposomal Mitoxantrone Used to Treat a Tumor Model Designed to Assess Drug Delivery to Liver Clin. Cancer Res., November 1, 2000; 6(11): 4449 - 4460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pagnan, D. D. Stuart, F. Pastorino, L. Raffaghello, P. G. Montaldo, T. M. Allen, B. Calabretta, and M. Ponzoni Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects J Natl Cancer Inst, February 2, 2000; 92(3): 253 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors Pharmacol. Rev., December 1, 1999; 51(4): 691 - 744. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
